Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Industry Succeed Now In Thrusting Comprehensive Reform Medtech Regulations To Top Of EU Agenda?

Executive Summary

It is no secret that there are significant problems in the implementation of the EU’s medtech regulations. But will EU regulators concede to industry’s latest lobbying efforts for fundamental change and accept this challenge as a starting point for discussions?

You may also be interested in...



Entire EU Medtech Industry Throws Weight Behind Argument To Structurally Reform MDR And IVDR

The European Commission has conceded to the medtech industry’s calls to delay and modify the new EU regulatory requirements multiple times over the last few years. But will it yield to fresh calls for radical changes being sought by the most powerful lobby yet?

EU Lists Its First Reference Laboratories For High-Risk IVDs Falling Into Class D

There are 10 listings in the first  group of EU reference laboratory to be named. They will not formally assess IVDs for about a year and even then only evaluate products that are in a later batch to comply with the IVD Regulation.

EU Regulatory Roundup, November 2023: Notified Body Advances But Sector Still Demands System Rethink

There is currently a melting pot of ideas concerning the future of the EU’s medtech regulatory system due to its shortfalls. All the while progress is being made, especially in the area notified bodies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel